Establishment and Characterization of a Brca1−/−, p53−/− Mouse Mammary Tumor Cell Line
Authors:
- Lilla HámoriLHLilla Hámori
- Gyöngyi KudlikGKGyöngyi Kudlik
- Kornélia SzebényiKSKornélia Szebényi
- Nóra KucsmaNKNóra Kucsma
- Bálint SzederBSBálint Szeder
- Ádám PótiÁPÁdám Póti
- Ferenc UherFUFerenc Uher
- György VáradyGVGyörgy Várady
- Dávid SzütsDSDávid Szüts
- József TóváriJTJózsef Tóvári
- András FürediAFAndrás Füredi
- Gergely SzakácsGSGergely Szakács
Open Access
- 11 February 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (4) , 1185
Abstract
Breast cancer is the most commonly occurring cancer in women and the second most common cancer overall. By the age of 80, the estimated risk for breast cancer for women with germline BRCA1 or BRCA2 mutations is around 80%. Genetically engineered BRCA1-deficient mouse models offer a unique opportunity to study the pathogenesis and therapy of triple negative breast cancer. Here we present a newly established Brca1−/−, p53−/− mouse mammary tumor cell line, designated as CST. CST shows prominent features of BRCA1-mutated triple-negative breast cancers including increased motility, high proliferation rate, genome instability and sensitivity to platinum chemotherapy and PARP inhibitors (olaparib, veliparib, rucaparib and talazoparib). Genomic instability of CST cells was confirmed by whole genome sequencing, which also revealed the presence of COSMIC (Catalogue of Somatic Mutations in Cancer) mutation signatures 3 and 8 associated with homologous recombination (HR) deficiency. In vitro sensitivity of CST cells was tested against 11 chemotherapy agents. Tumors derived from orthotopically injected CST-mCherry cells in FVB-GFP mice showed sensitivity to cisplatin, providing a new model to study the cooperation of BRCA1-KO, mCherry-positive tumor cells and the GFP-expressing stromal compartment in therapy resistance and metastasis formation. In summary, we have established CST cells as a new model recapitulating major characteristics of BRCA1-negative breast cancers.Keywords
Funding Information
- Magyar Tudományos Akadémia (Momentum)
- National Research, Development and Innovation Fund of Hungary (FIEK_16-1-2016-0005)
This publication has 105 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor ProfilingPLOS ONE, 2013
- Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cellsProceedings of the National Academy of Sciences of the United States of America, 2011
- Concise Review: Dissecting a Discrepancy in the Literature: Do Mesenchymal Stem Cells Support or Suppress Tumor Growth?Stem Cells, 2010
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProceedings of the National Academy of Sciences, 2008
- The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppressionProceedings of the National Academy of Sciences, 2008
- Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1 -mutated basal-like breast cancerProceedings of the National Academy of Sciences, 2007
- Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancerProceedings of the National Academy of Sciences, 2007
- Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β‐tubulinsInternational Journal of Cancer, 2007
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001